Summary of the effects of CMS and/or lurasidone on the activity, protein, and mRNA levels of liver CYP isoforms
↑,↓ Increase or decrease, respectively; (↑), (↓) a tendency to increase or decrease, respectively.
| CYP1A2 | CYP2A | CYP2B1 | CYP2B2 | CYP2C6 | CYP2C11 | CYP2D | CYP3A1 | CYP3A2 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CMS | Activity | No change | (↓) | ↓ | No change | No change | no change | ↓ | ||
| Protein | (↓) | ↓ | ↑ | ↓ | ||||||
| mRNA | (↑) | (↑) | No change | No change | No change | |||||
| Lurasidone (vs. nonstressed control) | Activity | No change | No change | (↓) | No change | ↓ | No change | No change | ||
| Protein | ↓ | ↓ | ↑ | No change | ||||||
| mRNA | ↑ | No change | No change | ↑ | ↑ | |||||
| CMS + Lurasidone (vs. stressed control) | Activity | (↑) | No change | ↑ | No change | ↓ | No change | ↑ | ||
| Protein | (↑) | No change | ↑ | No change | ||||||
| mRNA | (↓) | No change | No change | ↑ | ↑ | |||||